New antifungal drug APX001 passes first safety check in healthy volunteers
NCT ID NCT02956499
First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This early-stage study tested the safety and tolerability of a new antifungal drug called APX001 in about 80 healthy adults. Participants received either the drug or a placebo to check for side effects and how the drug moves through the body. The goal was to gather initial safety data, not to treat any infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
PRA Health Sciences
Groningen, 9728 NZ, Netherlands
-
PRA Health Sciences
Groningen, Netherlands
Conditions
Explore the condition pages connected to this study.